Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther. 2011; 19 :1048–1057.Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a ...
AAV2-GDNF) that is delivered to the putamen, and brings this therapeutic one step closer to potentially reaching patients. AB-1005 is also currently being investigated for the treatment of mild to moderate Parkinson'...
Matthew T. RoccoAsad S. AkhterDebra J. EhrlichGretchen C. ScottCodrin LunguVikas MunjalAnthony AquinoRussell R. LonserMassimo S. FiandacaMark Hallett
doi:10.1002/mds.29820Heiss, John D.Ray‐Chaudhury, AbhikKleiner, David E.Ehrlich, Debra J.Scott, GretchenEdwards, Nancy A.Goldstein, David S.Hammoud, Dima A.Hadaczek, PiotrVan Laar, Victor S.Movement Disorders